Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Recommendation of “Buy” by Analysts

Maze Therapeutics, Inc. (NASDAQ:MAZE) has earned a consensus rating of “Buy” from the eleven ratings firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and three have given a strong buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $44.50.

Several research analysts recently commented on the stock. HC Wainwright lifted their target price on shares of Maze Therapeutics from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, December 3rd. Wells Fargo & Company started coverage on Maze Therapeutics in a research report on Thursday, December 4th. They issued an “overweight” rating and a $55.00 price target on the stock. Wedbush lifted their price objective on Maze Therapeutics from $35.00 to $36.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. JPMorgan Chase & Co. boosted their price objective on Maze Therapeutics from $27.00 to $37.00 and gave the stock an “overweight” rating in a research report on Monday, September 29th. Finally, Wall Street Zen lowered Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 17th.

Maze Therapeutics Stock Performance

MAZE opened at $44.27 on Friday. The firm has a market cap of $2.13 billion and a P/E ratio of -2.12. The business has a 50 day moving average price of $39.90 and a 200 day moving average price of $27.97. Maze Therapeutics has a twelve month low of $6.71 and a twelve month high of $47.36.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.08.

Insider Activity

In other news, CMO Harold Bernstein sold 25,156 shares of the firm’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $40.20, for a total value of $1,011,271.20. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Amy Bachrodt sold 5,000 shares of the business’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $39.15, for a total transaction of $195,750.00. Following the transaction, the senior vice president directly owned 12,965 shares in the company, valued at $507,579.75. This trade represents a 27.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 167,500 shares of company stock valued at $6,774,667.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in shares of Maze Therapeutics by 218.1% during the third quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock valued at $34,615,000 after buying an additional 915,342 shares during the last quarter. Marshall Wace LLP increased its stake in Maze Therapeutics by 3,868.5% during the third quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock valued at $20,166,000 after acquiring an additional 758,104 shares during the period. ArrowMark Colorado Holdings LLC acquired a new position in Maze Therapeutics in the 3rd quarter valued at approximately $14,135,000. Frazier Life Sciences Management L.P. raised its holdings in Maze Therapeutics by 10.6% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock valued at $56,040,000 after acquiring an additional 438,274 shares in the last quarter. Finally, Balyasny Asset Management L.P. bought a new stake in shares of Maze Therapeutics in the 3rd quarter worth approximately $11,246,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.